According to a new report from Intel Market Research, the global Ustekinumab Biosimilars market was valued at USD 1.5 billion in 2025 and is projected to reach USD 3.2 billion by 2034, growing at a CAGR of 8.7% during the forecast period (2026–2034). This substantial growth reflects increasing demand for cost-effective biologic alternatives to treat autoimmune disorders like psoriasis,...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek